Eiger BioPharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Eiger Biopharmaceuticals

03/11/2022 21:03

* Eiger BioPharmaceuticals Inc  EIGR.OQ  reported a
quarterly
adjusted loss of 62 cents​​ per share for the quarter ended in
September. The mean expectation of five analysts for the quarter
was for a loss of 52 cents per share.
    * Revenue rose 32.4% to $4.02 million from a year ago;
analysts
expected $4.27 million. 
    * Eiger BioPharmaceuticals Inc's reported EPS for the
quarter was
a loss of 62 cents​.
    * The mean earnings estimate of analysts had risen by
about 5.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Eiger BioPharmaceuticals Inc shares had fallen by 36.0%
this
quarter and lost 7.1% so far this year.
    * The company reported a quarterly loss of $27.11 million.
    * Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $28.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 09:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.52          -0.62          Missed
 Jun. 30 2022      -0.61          -0.51          Beat
 Mar. 31 2022      -0.64          -0.64          Met
 Dec. 31 2021      -0.64          -0.64          Met